Olumiant
An oral daily medication used to treat rheumatoid arthritis, alopecia areata, and severe COVID-19.
Where Baricitinib is approved
All regulators →Of the three regulators tracked here, the first to approve Baricitinib was the EU, on 13 Feb 2017. It is approved in 3 of the 3 regulators tracked here.
- 1 EU safety letter (DHPC), latest: referral - article 20 procedure for Cibinqo / Jyseleca / Olumiant / Rinvoq / Xeljanz, 21 Feb 2023
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Baricitinib patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Baricitinib, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 6 listed patents; the last listed expires 30 Nov 2032 (US 9089574).
- Latest patent on the drug substance itself: 31 May 2032 (US 8158616).
Reproduced from the FDA Orange Book and Purple Book (checked 5 Oct 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Baricitinib
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Baricitinib works
All drug targets →- Tyrosine-protein kinase JAK1 inhibitor InhibitorTarget: JAK1 Janus kinase 1✓ In ChEMBL and the Guide to Pharmacology
- Tyrosine-protein kinase JAK2 inhibitor InhibitorTarget: JAK2 Janus kinase 2✓ In ChEMBL and the Guide to Pharmacology
- Alzheimer diseasePhase 3
- COVID-19Phase 3
- COVID-19–associated multisystem inflammatory syndrome in childrenPhase 3
- Cognitive impairmentPhase 3
- DyspneaPhase 3
- Exercise intolerancePhase 3
- Orthomyxoviridae infectious diseasePhase 3
- Acute respiratory distress syndromePhase 3
- Alopecia areataPhase 3
- Dengue diseasePhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2105759, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 7792, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Baricitinib
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 4 technology appraisals of Baricitinib. 4 are current, and 2 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) NICE TA982 | Terminated (no company submission) | 13 Jun 2024 | Current |
| Baricitinib for treating severe alopecia areata NICE TA926 | Not recommended | 25 Oct 2023 | Current |
| Baricitinib for treating moderate to severe atopic dermatitis NICE TA681 | Optimised | 3 Mar 2021 | Current |
| Baricitinib for moderate to severe rheumatoid arthritis NICE TA466 | Optimised | 9 Aug 2017 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Baricitinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 4 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: OlumiantEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Baricitinib
- ATC code
- L04AA37
- ChEMBL
- CHEMBL2105759
- DrugBank
- DB11817
- PubChem CID
- 44205240
- CAS number
- 1187594-09-7
- FDA UNII
- ISP4442I3Y
- Wikidata
- Q4860707
- Wikipedia
- Baricitinib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
What Olumiant is used for
Baricitinib (Olumiant) is an oral daily medication used to treat rheumatoid arthritis, alopecia areata, and severe COVID-19. It belongs to the JAK inhibitor class.
Related clinical trials recruiting now
Compare Olumiant with
Explore more
How this page is built
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
- FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
- Drugs@FDA ↗ First FDA approval date and the company holding the application
- FDA Drug Shortage Database ↗ Current US supply / shortage status
Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 11 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.